Epidemiology and surveillance of methicillinresistant staphylococcus aureus in Latin America

Brazilian Journal of Infectious Diseases

Volumn 14, Issue SUPPL. 2, 2010, Pages

  Mejía, Carlos ^a   Zurita, Jeannete ^b   Guzmán Blanco, Manuel ^c  

^a Roosevelt Hospital Guatemala   (Guatemala)

^b HOSPITAL VOZANDES   (Ecuador)

^c Centro Medico Docente La Trinidad   (Venezuela)

Author keywords

Epidemiology; Latin America; MRSA; Resistance; Surveillance

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; DISEASE SURVEILLANCE; HEALTH CARE FACILITY; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PREVALENCE; RISK FACTOR; SOUTH AND CENTRAL AMERICA; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; GENETICS; HEALTH SURVEY; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; LATIN AMERICA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; POPULATION SURVEILLANCE; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS;

EID: 78650817977     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1413-86702010000800003     Document Type: Article

References (61)

1. Guzmán-Blanco M, Mejía C, Isturiz R et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Latin America. Int J Antimicrob Agents. 2009; 34(4):304-8.
2. Rodriguez-Noriega E, Seas C, Guzmán-Blanco M et al. Evolution of methicillin-resistant Staphylococcus aureus clones in Latin America. Int J Infect Dis. 2010; 14:e560-6.
3. Leibovici L, Shraga I, Drucker M et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998; 244(5):379-86.
4. Kollef MH. Inadequate Antimicrobial Treatment: An Important Determinant of Outcome for Hospitalized Patients. Clin Infect Dis. 2000; 31(Suppl 4):S131-8.
5. Klevens RM, Edwards JR, Tenover FC et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006; 42(3):389-91.
6. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355(7):666-74.
7. ECDC. European Antimicrobial Resistance Surveillance System Annual Report 2007. (http://www.rivm.nl/earss/Images/EARSS%202007_FINAL_tcm61-55933.pdf) Accessed 18 October 2009.
8. Meyer E, Schwab F, Gastmeier P et al. Methicillin-resistant Staphylococcus aureus in German intensive care units during 2000-2003: data from Project SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance in Intensive Care Units). Infect Control Hosp Epidemiol. 2006; 27(2):146-54.
9. Pan American Conference on Antimicrobial Resistance in the Americas. Epidemiol Bull. 1999; 20(2):6-7.
10. CDC. MMWR Updated Guidelines for Evaluating Public Health Surveillance Systems: Recommendations from the Guidelines Working Group July 27, 2001. (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5013a1.htm) Accessed October 2009.
11. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003; 290(22):2976-84.
12. Turnidge JD, Bell JM. Methicillin-resistant Staphylococcal aureus evolution in Australia over 35 years. Microb Drug Resist. 2000; 6(3):223-9.
13. Gorwitz RJ. Understanding the success of methicillin-resistant Staphylococcus aureus strains causing epidemic disease in the community. J Infect Dis. 2008; 197(2):179-82.
14. Wang R, Braughton KR, Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med. 2007; 13(12):1510-4.
15. Mulvey MR, MacDougall L, Cholin B et al. Community-associated methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2005; 11(6):844-50.
16. David MZ, Glikman D, Crawford SE et al. What is community- associated methicillin-resistant Staphylococcus aureus? J Infect Dis. 2008; 197(9):1235-43.
17. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community- acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005; 5(5):275-86.
18. Flynn N, Cohen SH. The continuing saga of MRSA. J Infect Dis. 2008; 197(9):1217-9.
19. CDC. MRSA in healthcare settings. Department of Health and Human Services 2007. (http://www.cdc.gov/ncidod/dhqp/ar_MRSA_spotlight_2006.html) Accessed 10 November 2009.
20. Rossi F, Garcia P, Ronzon B et al. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis. 2008; 12(5):405-15.
21. Picao R, Sader H, Jones R et al. Analysis of resistance and vancomycin "reverse creep" in Latin American Staphylococcus aureus: ten-year report of the SENTRY Antimicrobial Surveillance Program (1997-2006). Clin Microbiol Infect. 2008; 14:S173.
22. Pan American Health Organisation. Annual report of the Monitoring/Surveillance Network for Resistance to Antibiotics, 2004. (http://www.paho.org/English/AD/DPC/CD/amr-2004.htm) Accessed 22 November 2009.
23. Pan-American Association of Infectious Diseases. Results of the 7th Survey of the Comitê de Resistência in Antimicrobials of API. Rev Panam de Infect. 2006; 8:48-51.
24. Sola C, Saka HA, Vindel A, Bocco JL. Emergence and Dissemination of a Community-Associated Methicillin-Resistant Panton-Valentine Leucocidin-Positive Staphylococcus aureus Clone Sharing the Sequence Type 5 Lineage with the Most Prevalent Nosocomial Clone in the Same Region of Argentina. J Clin Microbiol. 2008; 46(5):1826-31.
25. Loureiro MM, Graces B, Quadra M et al. Study of multidrug resistant microorganisms isolated from blood cultures of hospitalized newborns in Rio de Janeiro city, Brazil. Braz J Microbiol. 2002; 33:73-8.
26. Ribas RM, Freitas C, Gontijo Filho PP. Nosocomial bloodstream infections: organisms, risk factors and resistant phenotypes in the Brazilian University Hospital. Braz J Infect Dis. 2007; 11(3):351-4.
27. Melo DO, Sasaki M, Grinbaum RS. Vancomycin use in a hospital with high prevalence of methicillin-resistant Staphylococcus aureus: comparison with Hospital Infection Control Practices Advisory Committe Guidelines (HICPAC). Braz J Infect Dis. 2007; 11(1):53-6.
28. Lisboa T, Faria M, Hoher J et al. The prevalence of nosocomial infection in Intensive Care Units in the State of Rio Grande do Sul. Rev Bras Ter Intensiva 2007; 19(4):414-20.
29. Ruiz CM, Guerrero PJ, Romero PC. Etiology of ventilator-associated pneumonia in a university hospital. Association with comorbidity, previous use of antibiotics and mortality. Rev Chilena Infectol. 2007; 24:131-6.
30. Otth RL, Wilson SM, Bustamante HN et al. Antimicrobial susceptibility and resistance patterns of Staphylococcus aureus isolated from patients and carriers in Valdivia city, Chile. Rev Chilena Infectol. 2008; 25:175-8.
31. Buitrago G, Cortes JA, Castillo JS et al. Methicillin-resistant Staphylococcus aureus. Community-acquired phenotype spread in hospitals in Bogota, Colombia. Clin Microbiol Infect. 2008; 14:S411.
32. Ponce de Leon A, Amabile-Cuevas CF, Benitez A. In vitro activity of tigecycline and other antimicrobial drugs against selected pathogens isolated in Mexico. Clin Microbiol Infect. 2008; 14:S611.
33. Seas C, Hernandez K, Ramos R et al. Oxacillin-resistant and multidrug-resistant Staphylococcus aureus in Lima, Peru. Infect Control Hosp Epidemiol. 2006; 27(2):198-200.
34. Cuellar LE, Fernandez-Maldonado E, Rosenthal VD et al. Device-associated infection rates and mortality in intensive care units of Peruvian hospitals: findings of the International Nosocomial Infection Control Consortium. Rev Panam Salud Publica. 2008; 24(1):16-24.
35. Pfizer Venezuela S.A. Venezuelan program of surveillance of bacterial resistance to antobiotics; 1998-2006. (http://www.provenra.org) Accessed 17 May 2010.
36. Reyes J, Rincon S, Diaz L et al. Dissemination of methicillinresistant Staphylococcus aureus USA300 sequence type 8 lineage in Latin America. Clin Infect Dis. 2009; 49(12):1861-7.
37. Galiana VA. Infecciones por Staphylococcus aureus adquiridos en la comunidad. Arch Pediatr Urug 2003; 74:26-9.
38. Ribeiro A, Dias C, Silva-Carvalho MC et al. First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol. 2005; 43(4):1985-8.
39. Ma XX, Galiana A, Pedreira W et al. Community-acquired methicillin-resistant Staphylococcus aureus, Uruguay. Emerg Infect Dis. 2005; 11(6):973-6.
40. Alvarez CA, Barrientes OJ, Leal AL et al. Community-associated methicillin-resistant Staphylococcus aureus, Colombia. Emerg Infect Dis. 2006; 12(12):2000-1.
41. Guzmán-Lista MDC, Lozada-Oca RA. Detection of methicillin- resistant Staphylococcus aureus isolated from patients with nosocomials and community-acquired infections. Rev Soc Ven Microbiol. 2007; 27(1):349-63.
42. Noriega LM, Gonzalez P, Hormazabal JC et al. Community acquired infections with methicillin resistant strains of Staphylococcus aureus: report of five cases. Rev Med Chil. 2008; 136(7):885-91.
43. Palombarani S, Gardella N, Tuduri A et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in a hospital for acute diseases. Rev Argent Microbiol. 2007; 39(3):151-5.
44. Paganini H, Della Latta MP, Muller Opet B et al. Community- acquired methicillin-resistant Staphylococcus aureus infections in children: multicenter trial. Arch Argent Pediatr. 2008; 106(5):397-403.
45. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40(1):135-6.
46. Oliveira GA, Dell'Aquila AM, Masiero RL et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol. 2001; 22(7):443-8.
47. Palazzo IC, Araujo ML, Darini AL. First report of vancomycinresistant staphylococci isolated from healthy carriers in Brazil. J Clin Microbiol. 2005; 43(1):179-85.
48. Hageman JC, Patel J, Carey RC et al. Investigation and control of vancomycin-intermediate and -resistant Staphylococcus aureus: A Guide for Health Departments and Infection Control Personnel. 2006. (http://www.cdc.gov/ncidod/dhqp/pdf/ar/visa_vrsa_guide.pdf) Accessed 10 November 2009.
49. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement (M100-S19). 2009. Clinical and Laboratory Standards Institute. Wayne, PA. (http://www.clsi.org/source/orders/free/m100-s19.pdf) Accessed 23 November 2009.
50. Tenover FC, Moellering RC, Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007; 44(9):1208-15.
51. Sakoulas G, Moise-Broder PA, Schentag J et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6):2398-402.
52. Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999; 340(7):493-501.
53. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulasenegative staphylococci. J Clin Microbiol. 2003; 41(10):4740-4.
54. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988; 158(1):23-8.
55. Martinez-Aguilar G, Hammerman WA, Mason EO, Jr., Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillinsusceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003; 22(7):593-8.
56. van der Heijden IM, Sinto S, Oplustil SC, Mendes C. Occurrence of MLS resistance in staphylococcal and streptococcol clinical isolates. Abstract A-86. Presented at the 101st General Meeting of the American Society for Microbiology. Washington, DC, 2001.
57. Yilmaz G, Aydin K, Iskender S et al. Detection and prevalence of inducible clindamycin resistance in staphylococci. J Med Microbiol. 2007; 56(Pt 3):342-5.
58. Lewis JS, 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis. 2005; 40(2):280-5.
59. Siegel JD, Rhinehart E, Jackson M, Chiarello L. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control. 2007; 35(10 Suppl 2):S165-93.
60. Manian FA, Senkel D, Zack J, Meyer L. Routine screening for methicillin-resistant Staphylococcus aureus among patients newly admitted to an acute rehabilitation unit. Infect Control Hosp Epidemiol. 2002; 23(9):516-9.
61. CLSI. Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline-Third Edition (M39-A3) Clinical and Laboratory Standards Institute, Wayne, PA, 2009.